دورية أكاديمية
Cardio-Renal-Metabolic Outcomes Associated With the Use of GLP-1 Receptor Agonists After Heart Transplantation.
| العنوان: | Cardio-Renal-Metabolic Outcomes Associated With the Use of GLP-1 Receptor Agonists After Heart Transplantation. |
|---|---|
| المؤلفون: | Donald EM; Department of Medicine, Division of Cardiology New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA., Driggin E; Department of Medicine, Division of Cardiology New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA., Choe J; Department of Medicine, Division of Cardiology New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA., Batra J; Department of Medicine, Division of Cardiology New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA., Vargas F; Department of Medicine, Division of Cardiology New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA., Lindekens J; Department of Medicine, Division of Cardiology New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA., Fried JA; Department of Medicine, Division of Cardiology New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA., Raikhelkar JK; Department of Medicine, Division of Cardiology New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA., Bae DJ; Department of Medicine, Division of Cardiology New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA., Oh KT; Department of Medicine, Division of Cardiology New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA., Yuzefpolskaya M; Department of Medicine, Division of Cardiology New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA., Colombo PC; Department of Medicine, Division of Cardiology New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA., Latif F; Department of Medicine, Division of Cardiology New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA., Sayer G; Department of Medicine, Division of Cardiology New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA., Uriel N; Department of Medicine, Division of Cardiology New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA., Clerkin KJ; Department of Medicine, Division of Cardiology New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA., DeFilippis EM; Department of Medicine, Division of Cardiology New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA. |
| المصدر: | Clinical transplantation [Clin Transplant] 2024 Jul; Vol. 38 (7), pp. e15401. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Munksgaard Country of Publication: Denmark NLM ID: 8710240 Publication Model: Print Cited Medium: Internet ISSN: 1399-0012 (Electronic) Linking ISSN: 09020063 NLM ISO Abbreviation: Clin Transplant Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Copenhagen : Munksgaard, |
| مواضيع طبية MeSH: | Glucagon-Like Peptide-1 Receptor*/agonists , Heart Transplantation*/adverse effects, Humans ; Female ; Male ; Retrospective Studies ; Middle Aged ; Follow-Up Studies ; Prognosis ; Diabetes Mellitus, Type 2/drug therapy ; Glomerular Filtration Rate ; Hypoglycemic Agents/therapeutic use ; Kidney Function Tests ; Adult ; Postoperative Complications/drug therapy ; Graft Rejection/etiology ; Graft Rejection/prevention & control ; Graft Rejection/drug therapy ; Glucagon-Like Peptide-1 Receptor Agonists |
| مستخلص: | Background: The use of glucagon-like-peptide 1 receptor agonists (GLP1-RA) has dramatically increased over the past 5 years for diabetes mellitus type 2 (T2DM) and obesity. These comorbidities are prevalent in adult heart transplant (HT) recipients. However, there are limited data evaluating the efficacy of this drug class in this population. The aim of the current study was to describe cardiometabolic changes in HT recipients prescribed GLP1-RA at a large-volume transplant center. Methods: We retrospectively reviewed all adult HT recipients who received GLP1-RA after HT for a minimum of 1-month. Cardiometabolic parameters including body mass index (BMI), lipid panel, hemoglobin A1C, estimated glomerular filtration rate (eGFR), and NT-proBNP were compared prior to initiation of the drug and at most recent follow-up. We also evaluated for significant dose adjustments to immunosuppression after drug initiation and adverse effects leading to drug discontinuation. Results: Seventy-four patients were included (28% female, 53% White, 20% Hispanic) and followed for a median of 383 days [IQR 209, 613] on a GLP1-RA. The majority of patients (n = 56, 76%) were prescribed semaglutide. The most common indication for prescription was T2DM alone (n = 33, 45%), followed by combined T2DM and obesity (n = 26, 35%). At most recent follow-up, mean BMI decreased from 33.3 to 31.5 kg/m 2 (p < 0.0001), HbA1C from 7.3% to 6.7% (p = 0.005), LDL from 78.6 to 70.3 mg/dL (p = 0.018) and basal insulin daily dose from 32.6 to 24.8 units (p = 0.0002). Conclusion: HT recipients prescribed GLP1-RA therapy showed improved glycemic control, weight loss, and cholesterol levels during the study follow-up period. GLP1-RA were well tolerated and were rarely associated with changes in immunosuppression dosing. (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.) |
| References: | K. K. Khush, E. Hsich, L. Potena, et al., “The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty‐eighth Adult Heart Transplantation Report ‐ 2021; Focus on Recipient Characteristics,” The Journal of Heart and Lung Transplantation 40 (2021): 1035–1049. J. D. Newman, K. H. Schlendorf, Z. L. Cox, et al., “Post‐transplant Diabetes Mellitus Following Heart Transplantation,” The Journal of Heart and Lung Transplantation 41, no. 11 (2022): 1537–1546. Y. Sammour, M. Nassif, M. Magwire, et al., “Effects of GLP‐1 Receptor Agonists and SGLT‐2 Inhibitors in Heart Transplant Patients with Type 2 Diabetes: Initial Report from a Cardiometabolic Center of Excellence,” The Journal of Heart and Lung Transplantation 40, no. 6 (2021): 426–429. Y. Liu, F. A. Padilla, E. A. Graviss, et al., “Outcomes of Heart Transplant Recipients with Class II Obesity: A United Network for Organ Sharing Database Analysis,” Journal of Surgical Research 272 (2022): 69–78. M. R. Mehra, C. E. Canter, M. M. Hannan, et al., “The 2016 International Society for Heart Lung Transplantation Listing Criteria for Heart Transplantation: A 10‐year Update,” The Journal of Heart and Lung Transplantation 35, no. 1 (2016): 1–23. M. J. Russo, K. N. Hong, R. R. Davies, et al., “The Effect of Body Mass Index on Survival Following Heart Transplantation: Do Outcomes Support Consensus Guidelines?” Annals of Surgery 251, no. 1 (2010): 144–152. M. S. Khan, G. C. Fonarow, D. K. McGuire, et al., “Glucagon‐Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization,” Circulation 142, no. 12 (2020): 1205–1218. S. M. Dunlay, M. M. Givertz, D. Aguilar, et al., “Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement from the American Heart Association and Heart Failure Society of America,” Journal of Cardiac Failure 25, no. 8 (2019): 584–619. M. N. Kosiborod, S. Z. Abildstrom, B. A. Borlaug, et al., “Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity,” The New England Journal of Medicine 389, no. 12 (2023): 1069–1084. T. A. Zelniker, S. D. Wiviott, I. Raz, et al., “Comparison of the Effects of Glucagon‐Like Peptide Receptor Agonists and Sodium‐Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus,” Circulation 139, no. 17 (2019): 2022–2031. J. F. E. Mann, D. D. Orsted, and K. B. Frandsen, et al., “Liraglutide and Renal Outcomes in Type 2 Diabetes,” The New England Journal of Medicine 377, no. 9 (2017): 2197–2198. S. P. Marso, A. G. Holst, and T. Vilsboll, “Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes,” The New England Journal of Medicine 376, no. 9 (2017): 891–892. T. Sato, Y. Azuma, C. Ozone, et al., “Possible Advantage of Glucagon‐Like Peptide 1 Receptor Agonists for Kidney Transplant Recipients with Type 2 Diabetes,” The Journal of Clinical Endocrinology and Metabolism 108, no. 10 (2023): 2597–2603. A. Kukla, J. Hill, M. Merzkani, et al., “The Use of GLP1R Agonists for the Treatment of Type 2 Diabetes in Kidney Transplant Recipients,” Transplantation Direct 6, no. 2 (2020): e524. T. Thangavelu, E. Lyden, and V. Shivaswamy, “A Retrospective Study of Glucagon‐Like Peptide 1 Receptor Agonists for the Management of Diabetes after Transplantation,” Diabetes Therapy 11, no. 4 (2020): 987–994. P. Singh, T. E. Pesavento, K. Washburn, D. Walsh, and S. Meng, “Largest Single‐Centre Experience of Dulaglutide for Management of Diabetes Mellitus in Solid Organ Transplant Recipients,” Diabetes, Obesity & Metabolism 21, no. 4 (2019): 1061–1065. P. Singh, M. Taufeeq, T. E. Pesavento, K. Washburn, D. Walsh, and S. Meng, “Comparison of the Glucagon‐like‐peptide‐1 Receptor Agonists Dulaglutide and Liraglutide for the Management of Diabetes in Solid Organ Transplant: A Retrospective Study,” Diabetes, Obesity & Metabolism 22, no. 5 (2020): 879–884. M. R. Mehra, M. G. Crespo‐Leiro, A. Dipchand, et al., “International Society for Heart and Lung Transplantation Working Formulation of a Standardized Nomenclature for Cardiac Allograft Vasculopathy‐2010,” The Journal of Heart and Lung Transplantation 29, no. 7 (2010): 717–727. E. M. DeFilippis, K. K. Khush, M. A. Farr, A. Fiedler, A. Kilic, and M. M. Givertz, “Evolving Characteristics of Heart Transplantation Donors and Recipients: JACC Focus Seminar,” Journal of the American College of Cardiology 79, no. 11 (2022): 1108–1123. F. Foroutan, B. S. Doumouras, H. Ross, and A. C. Alba, “Impact of Pretransplant Recipient Body Mass Index on Post Heart Transplant Mortality: A Systematic Review and Meta‐analysis,” Clinical Transplantation 32, no. 8 (2018): e13348. A. Jalowiec, K. L. Grady, and C. White‐Williams, “Clinical Outcomes in Overweight Heart Transplant Recipients,” Heart & Lung 45, no. 4 (2016): 298–304. K. L. Grady, D. Naftel, S. V. Pamboukian, et al., “Post‐operative Obesity and Cachexia Are Risk Factors for Morbidity and Mortality after Heart Transplant: Multi‐institutional Study of Post‐operative Weight Change,” The Journal of Heart and Lung Transplantation 24, no. 9 (2005): 1424–1430. K. Miura, R. Yu, K. Sivapalan, et al., “Weight Gain after Heart Transplantation in Adults: Systematic Review and Meta‐Analysis,” ASAIO Journal 68, no. 9 (2022): 1107–1116. M. Hecking, A. Sharif, K. Eller, and T. Jenssen, “Management of Post‐transplant Diabetes: Immunosuppression, Early Prevention, and Novel Antidiabetics,” Transplant International 34, no. 1 (2021): 27–48. E. D. Michos, G. L. Bakris, H. W. Rodbard, and K. R. Tuttle, “Glucagon‐like Peptide‐1 Receptor Agonists in Diabetic Kidney Disease: A Review of Their Kidney and Heart Protection,” American Journal of Preventive Cardiology 14 (2023): 100502. A. J. Garber, “Incretin‐based Therapies in the Management of Type 2 Diabetes: Rationale and Reality in a Managed Care Setting,” The American Journal of Managed Care 16, no. supplement S7 (2010): S187–S194. A. R. Sadhu, S. S. Schwartz, and M. E. Herman, “The Rationale for Use of Incretins in the Management of New Onset Diabetes after Transplantation (Nodat),” Endocrine Practice 21, no. 7 (2015): 814–822. J. R. Lundgren, C. Janus, S. B. K. Jensen, et al., “Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined,” The New England Journal of Medicine 384, no. 18 (2021): 1719–1730. S. Verma, D. K. McGuire, S. C. Bain, et al., “Effects of Glucagon‐like Peptide‐1 Receptor Agonists Liraglutide and Semaglutide on Cardiovascular and Renal Outcomes across Body Mass Index Categories in Type 2 Diabetes: Results of the LEADER and SUSTAIN 6 Trials,” Diabetes, Obesity & Metabolism 22, no. 12 (2020): 2487–2492. A. R. G. Look, E. W. Gregg, J. M. Jakicic, et al., “Association of the Magnitude of Weight Loss and Changes in Physical Fitness with Long‐Term Cardiovascular Disease Outcomes in Overweight or Obese People with Type 2 Diabetes: A Post‐hoc Analysis of the Look AHEAD Randomised Clinical Trial,” The Lancet Diabetes & Endocrinology 4, no. 11 (2016): 913–921. M. J. Haykowsky, B. J. Nicklas, P. H. Brubaker, et al., “Regional Adipose Distribution and Its Relationship to Exercise Intolerance in Older Obese Patients Who Have Heart Failure with Preserved Ejection Fraction,” JACC: Heart Failure 6, no. 8 (2018): 640–649. D. W. Kitzman, P. Brubaker, T. Morgan, et al., “Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients with Heart Failure with Preserved Ejection Fraction: A Randomized Clinical Trial,” JAMA 315, no. 1 (2016): 36–46. S. L. Kristensen, R. Rorth, P. S. Jhund, et al., “Cardiovascular, Mortality, and Kidney Outcomes with GLP‐1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Meta‐analysis of Cardiovascular Outcome Trials,” The Lancet Diabetes & Endocrinology 7, no. 10 (2019): 776–785. N. Sattar, M. M. Y. Lee, S. L. Kristensen, et al., “Cardiovascular, Mortality, and Kidney Outcomes with GLP‐1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Meta‐analysis of Randomised Trials,” The Lancet Diabetes & Endocrinology 9, no. 10 (2021): 653–662. K. R. Tuttle, H. Bosch‐Traberg, D. Z. I. Cherney, et al., “Post Hoc Analysis of SUSTAIN 6 and PIONEER 6 Trials Suggests That People with Type 2 Diabetes at High Cardiovascular Risk Treated with Semaglutide Experience More Stable Kidney Function Compared with Placebo,” Kidney International 103, no. 4 (2023): 772–781. V. Perkovic, M. J. Jardine, B. Neal, et al., “Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy,” The New England Journal of Medicine 380, no. 24 (2019): 2295–2306. E. Muzurovic and D. P. Mikhailidis, “Impact of Glucagon‐like Peptide 1 Receptor Agonists and Sodium‐glucose Transport Protein 2 Inhibitors on Blood Pressure and Lipid Profile,” Expert Opinion on Pharmacotherapy 21, no. 17 (2020): 2125–2135. N. Marx, M. Husain, M. Lehrke, S. Verma, and N. Sattar, “GLP‐1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients with Type 2 Diabetes,” Circulation 146, no. 24 (2022): 1882–1894. A. Sharma, X. Zhao, B. G. Hammill, et al., “Trends in Noncardiovascular Comorbidities among Patients Hospitalized for Heart Failure: Insights from the Get with the Guidelines‐Heart Failure Registry,” Circulation: Heart Failure 11, no. 6 (2018): e004646. J. Harris, J. Teuteberg, and M. Shullo, “Optimal Low‐density Lipoprotein Concentration for Cardiac Allograft Vasculopathy Prevention,” Clinical Transplantation 32, no. 5 (2018): e13248. G. Iannuzzo, G. Cuomo, A. Di Lorenzo, et al., “Dyslipidemia in Transplant Patients: Which Therapy?” Journal of Clinical Medicine 11, no. 14 (2022): 4080. F. Sun, S. Chai, K. Yu, et al., “Gastrointestinal Adverse Events of Glucagon‐like Peptide‐1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta‐analysis,” Diabetes Technology & Therapeutics 17, no. 1 (2015): 35–42. |
| فهرسة مساهمة: | Keywords: diabetes; glucagon‐like peptide 1; heart transplantation; obesity; weight loss |
| المشرفين على المادة: | 0 (Glucagon-Like Peptide-1 Receptor) 0 (Hypoglycemic Agents) 0 (Glucagon-Like Peptide-1 Receptor Agonists) |
| تواريخ الأحداث: | Date Created: 20240718 Date Completed: 20240718 Latest Revision: 20240718 |
| رمز التحديث: | 20240718 |
| DOI: | 10.1111/ctr.15401 |
| PMID: | 39023081 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1399-0012 |
|---|---|
| DOI: | 10.1111/ctr.15401 |